Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.

Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, Corti D, Vogel L, Feng Y, Kim JO, Wang LF, Baric R, Lanzavecchia A, Curtis KM, Nabel GJ, Subbarao K, Jiang S, Dimitrov DS.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8. Epub 2007 Jul 9.

2.

Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.

Tsunetsugu-Yokota Y, Ohnishi K, Takemori T.

Rev Med Virol. 2006 Mar-Apr;16(2):117-31. Review.

PMID:
16518829
3.

Vaccine design for severe acute respiratory syndrome coronavirus.

He Y, Jiang S.

Viral Immunol. 2005;18(2):327-32. Review.

PMID:
16035944
4.

Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus.

Tan YJ, Lim SG, Hong W.

Antiviral Res. 2006 Nov;72(2):78-88. Epub 2006 Jun 6. Review.

PMID:
16820226
5.

Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.

Yeung KS, Yamanaka GA, Meanwell NA.

Med Res Rev. 2006 Jul;26(4):414-33. Review.

PMID:
16521129
6.

Molecular advances in severe acute respiratory syndrome-associated coronavirus (SARS-CoV).

Chow KY, Hon CC, Hui RK, Wong RT, Yip CW, Zeng F, Leung FC.

Genomics Proteomics Bioinformatics. 2003 Nov;1(4):247-62. Review.

7.

Current status of anti-SARS agents.

Shigeta S, Yamase T.

Antivir Chem Chemother. 2005;16(1):23-31. Review.

PMID:
15739619

Supplemental Content

Support Center